Recro Pharma (REPH) Downgraded by ValuEngine to “Hold”

Recro Pharma (NASDAQ:REPH) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

Other equities research analysts have also issued reports about the stock. Janney Montgomery Scott set a $13.00 price target on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Monday, October 1st. Oppenheimer set a $18.00 price target on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Wednesday, September 5th. Piper Jaffray Companies set a $10.00 price target on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Thursday, November 8th. Finally, Zacks Investment Research lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Recro Pharma currently has a consensus rating of “Buy” and a consensus price target of $12.88.

Shares of NASDAQ:REPH opened at $6.57 on Monday. Recro Pharma has a 12 month low of $4.78 and a 12 month high of $13.05. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 4.04. The firm has a market cap of $141.10 million, a P/E ratio of -3.30 and a beta of -0.51.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.03. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 220.42%. The firm had revenue of $18.28 million for the quarter, compared to analyst estimates of $16.77 million. Equities analysts expect that Recro Pharma will post -2.67 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in REPH. Oppenheimer & Co. Inc. acquired a new position in Recro Pharma in the second quarter valued at $154,000. Virtu Financial LLC acquired a new position in Recro Pharma in the third quarter valued at $156,000. Monarch Partners Asset Management LLC acquired a new position in Recro Pharma in the second quarter valued at $178,000. GSA Capital Partners LLP acquired a new position in Recro Pharma in the second quarter valued at $206,000. Finally, Alambic Investment Management L.P. increased its stake in Recro Pharma by 378.0% in the second quarter. Alambic Investment Management L.P. now owns 47,990 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 37,950 shares during the period. Hedge funds and other institutional investors own 52.81% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

See Also: What is the float in trading stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit